New diabetes clinical trial: HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Published on: 2026-05-28T04:00:00Z
Conditions: Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Resectable Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8
Interventions: Procedure: Biopsy Procedure; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Darizmetinib; Drug: Embolization Therapy; Procedure: Hepatectomy; Procedure: Magnetic Resonance Imaging; Drug: Placebo Administration; Procedure: Positron Emission Tomography
Sponsors: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting
https://ift.tt/ksg7yjX